Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...
1d
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors$15 ...
Hosted on MSN3d
KPMG's Swonk Sees No Fed Cuts Until 2026KPMG Chief Economist Diane Swonk doesn't expect to see a Federal Reserve interest rate cut until the middle of next year. She is on "Bloomberg The Close." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback